The new drug Cobenfy, formerly known as KarXT ... and are diagnosed with schizophrenia. Kramer said the FDA approval in treating schizophrenia may be only the beginning for the drug.

Jan. 31, 2025 – The FDA has approved a new non-opioid oral drug for acute pain in adults. It is the first new class of non-opioid pain medicine approved in over 20 years, providing effective ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...

2025 – The FDA has approved a new pill to treat adults with ... or a placebo plus chemoimmunotherapy. The new drug combination reduced the risk of disease progression or death by 27%, with ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in 2024. On 15 January, the two agencies ...

The Food and Drug Administration approved the first new drug in over 30 years to treat schizophrenia in adults. The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers ...